Mark Galbraith | Head of Quality Control & Analytical Sciences
Spark Therapeutics

Mark Galbraith, Head of Quality Control & Analytical Sciences, Spark Therapeutics

Mark Galbraith has worked in the biopharmaceutical industry for 20 years, where he has
gained diverse experience and knowledge in all phases of product development from preclinical
to commercial. Mark began his career at Merck & Co, where he held positions of
increasing responsibility in several functional areas related to vaccine clinical development
and vaccine commercial manufacturing including analytical R&D, regulatory sciences,
commercial analytical support, and quality control operations. Mark continued to develop
his career in quality control management and analytical development by directing the quality
control activities at Celldex Therapeutics, Bristol Myers-Squibb, and Gilead Sciences. Mark
has gained a broad knowledge of vaccines, biotechnology products, sterile
pharmaceuticals, and now gene therapy. Mark is currently serving as Head of Quality
Control and Analytical Sciences for Spark Therapeutics Inc. in Philadelphia, PA. Spark is a
leader in the field of gene therapy, seeking to transform the lives of patients by developing
potential one-time, life-altering treatments for debilitating genetic diseases.

Appearances:



World Orphan Drug Congress USA 2019 - Day 1 @ 16:00

Challenges in analytical development for gene therapy for rare diseases – Luxturna as a case study

last published: 20/Mar/19 21:45 GMT

back to speakers